Eli Lilly and Company LLY
1,183.46
1.57
0.13%
as of 25 Sep
- Market cap
- $1.11T
- P/E
- 39.7×
Follow LLY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Eli Lilly and Company (LLY) Gross margin
Eli Lilly and Company's gross margin over the twelve months to 30 June 2026 was 83.4%, up 0.4 percentage points from fiscal 2025 (83.0%). Over the past ten years it has ranged from 73.1% (fiscal 2016) to 83.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 72.8% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 83.0% | 1.73 |
| FY2024 | 81.3% | 2.06 |
| FY2023 | 79.3% | 2.48 |
| FY2022 | 76.8% | 2.59 |
| FY2021 | 74.2% | (3.48) |
| FY2020 | 77.7% | (1.19) |
| FY2019 | 78.9% | 0.63 |
| FY2018 | 78.2% | 0.49 |
| FY2017 | 77.7% | 4.64 |
| FY2016 | 73.1% | (1.67) |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 85.8% | 3.85 |
| Mar 2026 | 81.9% | (0.60) |
| Dec 2025 | 82.5% | (0.38) |
| Sep 2025 | 82.9% | (1.36) |
| 42 more quarters | Free account |
Against its own ten years
Low 73.1%
High 83.0%
Ten-year median
77.7%
Current reading's percentile
100
Gross margin against peers
| Company | Gross margin |
|---|---|
| LLY Eli Lilly and Company | 83.4% |
| AZN AstraZeneca PLC compare | 81.9% |
| GILD Gilead Sciences, Inc. compare | 79.6% |
| NVS Novartis AG compare | 74.7% |
| PFE Pfizer Inc. compare | 73.2% |
| MRK Merck & Co., Inc. compare | 73.0% |
| ABBV AbbVie Inc. compare | 71.5% |
| AMGN Amgen Inc. compare | 69.5% |
| JNJ Johnson & Johnson compare | 67.9% |
| Drug Manufacturers General industry median | 72.8% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on LLY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement